1-7 of 7
Norbert Hollaender
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Probability of Being in Response (PBR): A Novel Efficacy Endpoint for Chronic Graft Versus Host Disease (GvHD) Applied to the Reach-3 Study of Ruxolitinib Versus BAT

Norbert Hollaender, Ekkehard Glimm, Jennifer Gauvin, Tommaso Stefanelli, Robert Zeiser
Journal: Blood
Blood (2022) 140 (Supplement 1): 10521–10522.
https://doi.org/10.1182/blood-2022-159432
Published: 2022
Journal Articles

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Robert Zeiser, PhD, Nicola Polverelli, MD PhD, Ron Ram, MD, Shahrukh K. Hashmi, MDMPH, Ronjon Chakraverty, BMBS, PhD, Mary E. D. Flowers, MD, Fitzroy Dawkins, MD, Norbert Hollaender, MD, Maanasa Gowda, PharmD, Tommaso Stefanelli, MD, Stephanie J. Lee, MDMPH, Takanori Teshima, MD, Franco Locatelli, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–24.
https://doi.org/10.1182/blood-2020-137694
Published: 2020
Journal Articles

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study

Clinical Trials & Observations
Ali T. Taher, Zeynep Karakas, Elena Cassinerio, Noppadol Siritanaratkul, Antonis Kattamis, Aurelio Maggio, Stefano Rivella, Norbert Hollaender, Bruyère Mahuzier, Brian Gadbaw, Yesim Aydinok
Journal: Blood
Blood (2018) 131 (2): 263–265.
https://doi.org/10.1182/blood-2017-06-790121
Published: 2018
Includes: Supplemental data
Journal Articles

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Yesim Aydinok, MD, Zeynep Karakas, MD, Elena Cassinerio, MD, Noppadol Siritanaratkul, MD, Antonis Kattamis, MD, Aurelio Maggio, MD, Norbert Hollaender, PhD, Bruyère Mahuzier, Pharm D, Brian Gadbaw, MD, Ali T. Taher, MD PhD
Journal: Blood
Blood (2016) 128 (22): 852.
https://doi.org/10.1182/blood.V128.22.852.852
Published: 2016
Journal Articles

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts

Clinical Trials & Observations Brief Report
Francesco Passamonti, Margherita Maffioli, Francisco Cervantes, Alessandro Maria Vannucchi, Enrica Morra, Tiziano Barbui, Domenica Caramazza, Lisa Pieri, Elisa Rumi, Heinz Gisslinger, Laurent Knoops, Jean Jaques Kiladjian, Barbara Mora, Norbert Hollaender, Cristiana Pascutto, Claire Harrison, Mario Cazzola
Journal: Blood
Blood (2014) 123 (12): 1833–1835.
https://doi.org/10.1182/blood-2013-12-544411
Published: 2014
Journal Articles

Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts

Francesco Passamonti, MD, Margherita Maffioli, MD, Francisco Cervantes, MD, PhD, Alessandro M. Vannucchi, MD, PhD, Enrica Morra, MD, Tiziano Barbui, MD, Caramazza Domenica, MD, Elisa Rumi, MD, Gisslinger Heinz, Laurent Knoops, MD, PhD, Barbara Mora, MD, Norbert Hollaender, PhD, Margaret Squier, MD, PhD, Cristiana Pascutto, Claire N Harrison, DM, FRCP, FRCPath, Mario Cazzola, MD
Journal: Blood
Blood (2013) 122 (21): 4066.
https://doi.org/10.1182/blood.V122.21.4066.4066
Published: 2013
Journal Articles

Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study

Claire N. Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD, PhD, Heinz Gisslinger, MD, Dietger Niederwieser, MD, Francesco Passamonti, MD, Roger J. Waltzman, MD, Norbert Hollaender, PhD, Deborah S. Hunter, PhD, Richard S. Levy, MD, Laurent Knoops, MD, PhD, Francisco Cervantes, MD, PhD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD, Giovanni Barosi, MD
Journal: Blood
Blood (2011) 118 (21): 279.
https://doi.org/10.1182/blood.V118.21.279.279
Published: 2011